Recombinant DNA Approaches to Feline Leukemia Virus Immunization
Retrovirus vaccines are in the limelight now more than ever before due to the etiologic involvement of retroviruses, human T-lymphotropic virus (HTLV-III/LAV) in the acquired immunodeficiency syndrome (AIDS) of man (1,5) and HTLV-I in certain human lymphomas (14). Experience with retrovi ruses and other viral vaccines in animal models is thus of great importance in guiding the way toward the most effective procedures for immunizing humans. Conventional vaccine approaches with inactivated or live attenuated retroviruses have been successful in some circumstances (7). However, these vaccines pose a number of economic and safety problems, primarily because of the tissue culture requirement for growing viruses. In view of these considerations, the new recombinant DNA technology offers the advantage of producing synthetic vaccines of greater purity, stability, safety, and cost-effectiveness (13). Researchers in private industry are playing an important role in developing such products.
KeywordsLive Virus Envelope Gene Persistent Viremia Detectable Viremia Modify Live Virus
Unable to display preview. Download preview PDF.
- 1.Barré-Sinoussi, F., J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Ve’zinet-Brun, C. Rouzious, W. Rosenbaum, and L. Montagnier (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syn-drome (AIDS). Science 220:868–871.PubMedCrossRefGoogle Scholar
- 2.Coffin, J. (1982) Structure of the retroviral genome. In RNA Tumor Viruses, R. Weiss, N. Teich, H. Varmus, and J. Coffin, eds. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 261–268.Google Scholar
- 5.Gallo, R.C., S.Z. Salahuddin, M. Popovic, G.M. Shearer, M. Kaplan, B.F. Haynes, T.J. Palker, R. Redfield, J. Oleske, B. Safai, G. White, P. Foster, and P.D. Markham (1984) Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500–502.PubMedCrossRefGoogle Scholar
- 6.Gardner, M.B., and P. Marx (1985) Simian acquired immunodeficiency syndrome. Adv. Viral Onc. 5:57–81.Google Scholar
- 7.Gardner, M.B., N. Pedersen, P. Marx, R. Henrickson, P. Luciw, and R. Gilden (1985) Vaccination against virally induced animal tumors. In Immunity To Cancer, A.E. Reif and M.S. Mitchell, eds. Academic Press, New York, pp. 605–617.Google Scholar
- 8.Hardy, Jr., W.D., P.W. Hess, E.G. MacEwen, A.J. McClelland, E.E. Zuckerman, M. Essex, S.M. Cotter, and O. Jarrett (1976) Biology of fe-line leukemia virus in the natural environment. Cane. Res. 36:582–588.Google Scholar
- 9.Jarrett, O. (1974) Feline leukemia virus subgroups. In Feline Leukemia Virus, W.D. Hardy and A.J. McClelland, eds. Elsevier/North Holland, Amsterdam, pp. 473–479.Google Scholar
- 11.Lutz, H., N.C. Petersen, and G.H. Theilen (1983) Course of feline leukemia virus infection and its detection by enzyme-linked immunosorbent assay and monoclonal antibodies. Am. J. Vet. Med. 44(11):2054–2059.Google Scholar
- 12.Mathes, L.E., M.G. Lewis, and R.G. Olsen (1980) Immunoprevention of feline leukemia: Efficacy testing and antigenic analysis of soluble tumor-cell antigen vaccine. In Feline Leukemic Virus, W.D. Hardy and A.J. McClelland, eds. Elsevier/North Holland, Amsterdam, pp. 211–216.Google Scholar